Filing Flows › Sight Sciences (SGHT) › Q1 2025
Sight Sciences (SGHT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Sight Sciences (SGHT) reported revenue of $17.5M for the first quarter 2025 (Q1 2025), -9% from a year earlier and -8% from the quarter before. Operating margin was -79.2%, net loss $14.2M (80.8% of revenue).
Sight Sciences, Q1 2025: revenue $17.5M (-9% year over year), operating margin -79.2%, net loss $14.2M, operating cash flow −$11.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.5M | -8% | -9% |
| Operating profit | −$13.9M | — | — |
| Net earnings | −$14.2M | — | — |
| Operating cash flow | −$11.6M | — | — |
What changed
Revenue was $17.5M in Q1 2025, down 9% year over year and down 8% from the previous quarter. Surgical Glaucoma was the largest line at 98% of revenue. Surgical Glaucoma lost $1.1M year over year (down 6%), 65% of the total change.
Gross margin was 86.2%, up 0.7 points from a year earlier. Operating costs exceeded revenue by $13.9M, an operating margin of -79.2%. Operating expenses fell 7% while revenue fell 9%. The quarter ended with a net loss of $14.2M, wider than the previous quarter's $11.8M loss.
Operating cash flow was −$11.6M. Non-cash charges added back $149K of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items used $1.8M.
Questions
What was Sight Sciences' revenue in the first quarter 2025?
Sight Sciences (SGHT) reported revenue of $17.5M for the first quarter 2025 (Q1 2025), -9% from a year earlier and -8% from the quarter before.
Was Sight Sciences profitable in the first quarter 2025?
Operating loss was $13.9M (-79.2% of revenue) and net loss $14.2M.
Source: Sight Sciences 10-Q on SEC EDGAR.